A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Türk, Murat
• dc.contributor.author Kocatürk, Emek
• dc.contributor.author Ertas, Ragip
• dc.contributor.author Ensina, Luis Felipe
• dc.contributor.author Ferrucci, Silvia M.
• dc.contributor.author Grattan, Clive
• dc.contributor.author Vestergaard, Christian
• dc.contributor.author Zuberbier, Torsten
• dc.contributor.author Maurer, Marcus
• dc.contributor.author Giménez Arnau, Anna Maria
• dc.date.accessioned 2024-10-09T06:24:59Z
• dc.date.available 2024-10-09T06:24:59Z
• dc.date.issued 2024
• dc.description.abstract Background: Although there have been significant advances in the treatment of chronic spontaneous urticaria (CSU) in recent years, there remains a lack of clear guidance on when and how to step down treatment in responders. This study aims to investigate stepping down approaches of different steps of CSU treatment from a global perspective. Methods: "Stepping down chronic spontaneous urticaria treatment" (SDown-CSU) is an international, multicenter, observational, cross-sectional, survey-based study of the Urticaria Centers of Reference and Excellence (UCARE) network. The questionnaire included 48 questions completed by physicians in the UCARE network. Results: Surveys completed by 103 physicians from 81 UCAREs and 34 countries were analyzed. Seventy-eight percent of the participants responded that they had a national urticaria management guideline written by their professional societies and 28% responded that they had to operate under a regulatory guideline proposed by central health funding organizations. Seventy-two and 58.7% of these national recommendations do not contain any detailed information on when and/or how CSU treatment should be discontinued. There was a lack of detailed information on antihistamines and cyclosporine in particular. A predefined maximum duration was generally not applicable to omalizumab and cyclosporine (81% and 82%, respectively). Nearly all UCAREs step down omalizumab within 6 months from the first controlled status and 42% discontinue cyclosporine after 6 months regardless of the control status. Conclusions: The findings from the SDown-CSU study clearly highlight a global need for guidance on the process of stepping down treatment in CSU. Additionally, the study offers a step-down algorithm applicable to all stages of CSU treatment.
• dc.format.mimetype application/pdf
• dc.identifier.citation Türk M, Kocatürk E, Ertaş R, Ensina LF, Mariel Ferrucci S, Grattan C, et al. A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU study. Clin Transl Allergy. 2024 Feb;14(2):e12343. DOI: 10.1002/clt2.12343
• dc.identifier.doi http://dx.doi.org/10.1002/clt2.12343
• dc.identifier.issn 2045-7022
• dc.identifier.uri http://hdl.handle.net/10230/61356
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.ispartof Clin Transl Allergy. 2024 Feb;14(2):e12343
• dc.rights © 2024 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Antihistamine
• dc.subject.keyword Chronic urticaria
• dc.subject.keyword Cyclosporine
• dc.subject.keyword Guideline
• dc.subject.keyword Omalizumab
• dc.subject.keyword Step down
• dc.subject.keyword Urticaria control test
• dc.title A global perspective on stepping down chronic spontaneous urticaria treatment: Results of the Urticaria Centers of Reference and Excellence SDown-CSU study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion